QUCY
QUCY
Mainz Biomed N.V.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $2.46M | $-5.08M | 0% | $-0.43 | $-2.46M |
What's going well?
The company is still investing in research and development, which could pay off if it finds a way to generate sales in the future. Debt costs are low, so interest payments aren't a big problem.
What's concerning?
QUCY had zero revenue and lost over $5 million, including a large one-time loss. Operating expenses are high, and there's no sign yet of a turnaround or a working business model.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $4.45M ▲ | $7.72M ▲ | $3.13M ▼ | $4.59M ▲ |
| Q4-2025 | $889.09K ▼ | $5.33M ▼ | $4.69M ▼ | $641.6K ▼ |
| Q2-2025 | $1.91M ▼ | $9.8M ▼ | $7.28M ▲ | $2.52M ▼ |
| Q4-2024 | $6.24M ▲ | $13.24M ▲ | $7.19M ▼ | $6.05M ▲ |
| Q2-2024 | $977.76K | $8.45M | $12.59M | $-4.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-2.49M | $-2.71M | $-650.66K | $7.27M | $-2.62M | $-2.71M |
What's strong about this company's cash flow?
The company still has $4.45 million in cash, and working capital changes provided a temporary boost to cash flow. It is able to raise money from investors when needed.
What are the cash flow concerns?
Operations are burning cash at a high rate, and the company is only staying afloat by issuing new shares, which dilutes existing shareholders. Cash reserves are shrinking fast, and there's no sign of self-sustaining operations.
5-Year Trend Analysis
A comprehensive look at Mainz Biomed N.V.'s financial evolution and strategic trajectory over the past five years.
QUCY combines a track record of developing sophisticated technology with a willingness to rethink its strategy and pivot into new, potentially high‑growth areas. It has positive gross margins on its existing products, meaningful intangible assets, and leadership with deep experience in homeland security and federal systems. The company has shown an ability to raise equity capital and to secure exclusive rights to promising technologies such as autonomous drones, which could serve as building blocks for a differentiated defense‑tech platform.
The financial profile is fragile: heavy operating losses, persistent cash burn, weak liquidity, high leverage, and a long history of accumulated deficits. The strategic pivot abandons a known, if challenging, diagnostics path for an entirely new competitive landscape, where the company currently lacks a proven track record, established customer relationships, or stable revenue base. Execution risk around integrating new technologies, winning and delivering on defense contracts, and funding ongoing operations without excessive dilution is substantial.
The outlook for QUCY is highly uncertain and largely dependent on its ability to execute its quantum‑cyber and defense strategy while managing financial risk. If the company successfully commercializes its drone and cybersecurity technologies and secures meaningful defense contracts, its prospects could improve markedly from today’s low revenue base. However, the combination of significant cash burn, leveraged balance sheet, and the inherent difficulty of breaking into defense and quantum‑cyber markets means the path forward is likely to be volatile, with a wide range of possible outcomes.
About Mainz Biomed N.V.
http://mainzbiomed.comMainz Biomed NV is a molecular genetics cancer diagnostic company. The firm is engaged in the developing of market-ready molecular genetic diagnostic solutions for life-threatening conditions. It is involved in the commercializing of its product portfolio in Europe, the United States, and the rest of world. The company was founded on March 08, 2021 and is headquartered in Mainz, Germany.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q1-2026 | $0 | $2.46M | $-5.08M | 0% | $-0.43 | $-2.46M |
What's going well?
The company is still investing in research and development, which could pay off if it finds a way to generate sales in the future. Debt costs are low, so interest payments aren't a big problem.
What's concerning?
QUCY had zero revenue and lost over $5 million, including a large one-time loss. Operating expenses are high, and there's no sign yet of a turnaround or a working business model.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q1-2026 | $4.45M ▲ | $7.72M ▲ | $3.13M ▼ | $4.59M ▲ |
| Q4-2025 | $889.09K ▼ | $5.33M ▼ | $4.69M ▼ | $641.6K ▼ |
| Q2-2025 | $1.91M ▼ | $9.8M ▼ | $7.28M ▲ | $2.52M ▼ |
| Q4-2024 | $6.24M ▲ | $13.24M ▲ | $7.19M ▼ | $6.05M ▲ |
| Q2-2024 | $977.76K | $8.45M | $12.59M | $-4.14M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q1-2026 | $-2.49M | $-2.71M | $-650.66K | $7.27M | $-2.62M | $-2.71M |
What's strong about this company's cash flow?
The company still has $4.45 million in cash, and working capital changes provided a temporary boost to cash flow. It is able to raise money from investors when needed.
What are the cash flow concerns?
Operations are burning cash at a high rate, and the company is only staying afloat by issuing new shares, which dilutes existing shareholders. Cash reserves are shrinking fast, and there's no sign of self-sustaining operations.
5-Year Trend Analysis
A comprehensive look at Mainz Biomed N.V.'s financial evolution and strategic trajectory over the past five years.
QUCY combines a track record of developing sophisticated technology with a willingness to rethink its strategy and pivot into new, potentially high‑growth areas. It has positive gross margins on its existing products, meaningful intangible assets, and leadership with deep experience in homeland security and federal systems. The company has shown an ability to raise equity capital and to secure exclusive rights to promising technologies such as autonomous drones, which could serve as building blocks for a differentiated defense‑tech platform.
The financial profile is fragile: heavy operating losses, persistent cash burn, weak liquidity, high leverage, and a long history of accumulated deficits. The strategic pivot abandons a known, if challenging, diagnostics path for an entirely new competitive landscape, where the company currently lacks a proven track record, established customer relationships, or stable revenue base. Execution risk around integrating new technologies, winning and delivering on defense contracts, and funding ongoing operations without excessive dilution is substantial.
The outlook for QUCY is highly uncertain and largely dependent on its ability to execute its quantum‑cyber and defense strategy while managing financial risk. If the company successfully commercializes its drone and cybersecurity technologies and secures meaningful defense contracts, its prospects could improve markedly from today’s low revenue base. However, the combination of significant cash burn, leveraged balance sheet, and the inherent difficulty of breaking into defense and quantum‑cyber markets means the path forward is likely to be volatile, with a wide range of possible outcomes.

CEO
Guido Baechler
Compensation Summary
(Year )
Upcoming Earnings
Ratings Snapshot
Rating : C

